Jane Street Group LLC bought a new stake in shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) in the third quarter, Holdings Channel reports. The fund bought 44,124 shares of the company’s stock, valued at approximately $55,000.
Co-Diagnostics Stock Performance
Co-Diagnostics stock opened at $0.74 on Thursday. The company’s 50-day moving average price is $0.89 and its 200-day moving average price is $1.14. Co-Diagnostics, Inc. has a twelve month low of $0.67 and a twelve month high of $2.23.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “neutral” rating and issued a $1.50 target price on shares of Co-Diagnostics in a research report on Monday, November 11th.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.
Featured Stories
- Five stocks we like better than Co-Diagnostics
- 3 Dividend Kings To Consider
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- Investing In Preferred Stock vs. Common Stock
- How Do Stock Buybacks Affect Shareholders?
- The Significance of Brokerage Rankings in Stock Selection
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Want to see what other hedge funds are holding CODX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report).
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
